European Journal of Nuclear Medicine

, Volume 12, Issue 10, pp 510–514

99mTc-MAG3, a new renal imaging agent: Preliminary results in patients

  • Andrew TaylorJr.
  • Dennis Eshima
  • Naomi Alazraki
Article

Abstract

99mTc-mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical which has been shown to have biological properties similar to131I-hippurate (OIH) in animals and volunteers.99mTc-MAG3 has now been compared with131I-orthoiodohippurate (OIH) in a group of patients with varying degrees of renal impairment. In all cases, the99mTc-MAG3 images were superior regardless of serum creatinine. Selected examples are illustrated including scans and renogram curves in a normal volunteer, transplant patients with creatinines of 9.8 mg/dl and 2.6 mg/dl respectively, and a furosemide study in a patient with questionable obstruction. Our preliminary results suggest that99mTc-MAG3 performs well in patients with impaired renal function and may well provide an acceptable replacement for OIH. A kit formulation has been developed and will soon be undergoing clinical evaluation.

Key words

MAG3 Mercaptoacetyltriglycine 99mTc-Renal radiopharmaceuticals OIH 131I-orthoiodohippurate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barbour GL, Crumm CK, Boyd CM, (1976) Comparison of inulin, iothalamate, and99mtechnetium DTPA for measurement of glomerular filtration rate. J Nucl Med 17:317–320Google Scholar
  2. Blaufox MD, Potchen EJ, Merrill JP (1967) Measurement of effective renal plasma flow in man by external counting methods. J Nucl Med 8:77–85Google Scholar
  3. Chervu RL, Sundoro BM, Blaufox MD (1984) Technetium-99m labeled p-aminohippuric acid analog: a new renal agent: Concise communication. J Nucl Med 25:1111–1115Google Scholar
  4. Davison A, Jones A, Orvig C, Sohn M (1981) A new class of oxotechnetium (+5) chelate complexes containing a TcON2S2 core. Inorg Chem 20:1629–1632Google Scholar
  5. Fritzberg AR, Kasina S, Eshima D (1986) Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med 27:111–116Google Scholar
  6. Fritzberg AR, Klingensmith WS, Whitney WP, Kuni CC (1981) Chemical and biological studies of Tc-99m N, N′-bis(mercaptoacetamido)-ethylenediamine: A potential replacement for I-131 hippuran. J Nucl Med 22:258–263Google Scholar
  7. Fritzberg AR, Kuni CC, Klingensmith WC, (1982) Synthesis and biological evaluation of Tc-99m N, N′-bis(mercaptoacetyl)-2,3-diaminopropanoate A potential replacement for (I-131)-o-iodohippurate. J Nucl Med 23:592–598Google Scholar
  8. Klingensmith WC, Fritzberg AR, Spitzer VM, (1983) Clinical evaluation of Tc-99m N,N′-bis(mercaptoacetyl)-2 3-diaminopropanoate as a replacement for I-131 hippuran. J Nucl Med 24: P 80Google Scholar
  9. Klingensmith WC III, Gerhold JP, Fritzberg AR, (1982) Clinical comparison of TC-99m N,N′-bis(mercaptoacetamido)-ethyl-enediamine and [131I] ortho-iodohippurate for evaluation of renal tubular function: Concise communication. J Nucl Med 23:377–380Google Scholar
  10. Klopper JF, Hauser W, Atkins HL, (1972) Evaluation of99mTc-DTPA for the measurement of glomerular filtration rate. J Nucl Med 8:77–85Google Scholar
  11. Marcus CS, Kuperus JH (1985) Pediatric Renal I-123 Orthoiodo-hippurate dosimetry. J Nucl Med 26:1211–1214Google Scholar
  12. McAfee JG, Grossman ZD, Gagne GR, (1981) Comparison of renal extraction efficiencies for radioactive agents in the normal dog. J Nucl Med 22:333–338Google Scholar
  13. Sapirstein LA, Vidt D, Mandel M (1955) Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol 181:330Google Scholar
  14. Stadalnik RC, Vogel JM, Jansholt A-L, Krohn KA, Matolo NM, Lagunas-Solar MC, Zielinski FW (1980) Renal clearance and extraction parameters of ortho-iodohippurate (I-123) compared with OIH (I-131) and PAH. J Nucl Med 21:168–170Google Scholar
  15. Taylor AT (1980) Quantitative renal function scanning: A historical and current status report on renal radiopharmaceuticals. In: Freeman LM, Weissman HS (eds) Nuclear Medicine Annual 1980. Raven Press, New York, pp 303–340Google Scholar
  16. Taylor A, Eshima D, Christian PC (1986a) Comparison of Tc-99m mercaptoacetyltriglycine (MAG3) and OIH in normal subjects and patients. J Nucl Med 27:962 (abstr)Google Scholar
  17. Taylor A, Eshima D, Fritzberg AR, (1986b) Comparison of I-131 OIH and Tc-99m MAG3 renal imaging in volunteers. J Nucl Med 27:795–803Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Andrew TaylorJr.
    • 1
  • Dennis Eshima
    • 1
  • Naomi Alazraki
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyEmory University HospitalAtlantaUSA

Personalised recommendations